Ireland· IE-PA-PA22579/007/002
Nintedanib Teva 150 mg soft capsules
A nintedanib product containing nintedanib esylate, registered in Ireland by TEVA GmbH. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Nintedanib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EX09 (nintedanib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Nintedanib · ATC L01EX09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of nintedanib costs, country by country.
Normalised to the WHO defined daily dose (0.38 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Nintedanib · price per daily dose (0.38 g)
USD · FX 28 Sept 2026
- US United States$51.13 (acquisition cost)
- CH Switzerland$34.12
The record
At a glance
HPRA (Ireland)- Active substance
- Nintedanib esylate
- Manufacturer
- TEVA GmbH
- Country
- Ireland (IE)
- ATC code
- L01EX09
- ATC class
- Nintedanib
- Defined daily dose
- 0.38 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA22579/007/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
160 interactions on record for nintedanib.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nintedanib · interactions on record
160 records
- 21 severe
- 139 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- DexamethasoneH02AB02severe
- RifampicinJ04AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nintedanib in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNINTEDANIB ACCORDAccord Healthcare S.L.U., Barcelona
- FinlandNintedanib AccordAccord Healthcare S.L.U.
- BelgiumNintedanib Accord 150 mgAccord Healthcare
- SwedenNintedanib Bioglan 150 mg Kapsel, mjukBioglan AB
- NorwayNintedanib ZentivaZentiva k.s.
- United StatesnintedanibEPIC PHARMA LLC
- GermanyNintedanib AlAliud Pharma Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 16 EEA countries. Names it is sold under:
- Austria · Nintedanib Accordpharma, Nintedanib Ratiopharm
- Cyprus · Nintedanib Teva
- Germany · Nintedanib Al, Nintedanib Ipf Al
- Denmark · Nintedanib Bioglan, Nintedanib Teva
- Estonia · Nintedanib Stada
- Finland · Bioglan, Nintedanib Bioglan
- United Kingdom (Northern Ireland) · Nintedanib, Nintedanib Eugia (Uk)
- Hungary · Lunidoc
- Iceland · Nintedanib Demo
- Luxembourg · Nintedanib Teva
- Netherlands · Nintedanib Reig Jofre, Nintedanib Tillomed
- Norway · Nintedanib Zentiva
- Portugal · Nintedanib Bravet, Nintedanib Teva Pharma
- Romania · Gevesla, Nintedanib Teva
- Sweden · Nintedanib Bioglan, Nintedanib Teva Gmbh
- Slovakia · Gevesla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aa9e3f07-d467-453c-bb23-c90deef605d4 GET /v1/drugs/aa9e3f07-d467-453c-bb23-c90deef605d4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, soft",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01EX09"
],
"strength": null,
"pa_number": "PA22579/007/002",
"substances": [
"Nintedanib esylate"
],
"legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "08/11/2024",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": "IC0206-062-001"
}See everything about nintedanib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.